Pulmonary Hypertension: second part (Diagnosis Approach)

Hipertensión pulmonar: Segunda entrega (Enfoque Diagnóstico)

Published 2006-06-01

Open | Download
PDF (Spanish) FLIP
Issue
Vol. 18 No. 2 (2006)
Section
Revisión de tema
How to Cite
Pulmonary Hypertension: second part (Diagnosis Approach).
rev. colomb. neumol. [Internet]. 2006 Jun. 1 [cited 2024 Nov. 24];18(2):92-9.
DOI
license
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo  los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.

Frank B. Pernett A.
Especialista Medicina Interna y Neumología, Servicio de Neumología, Hospital Militar Central, Bogota
    Robin Alonso Rada Escobar
    Especialista Medicina Interna y Neumología, Coordinador Académico de Medicina Interna, Servicio de Medicina Interna, Hospital Militar Central, Bogota
      Show authors biography

      Los mayores obstáculos para establecer un diagnostico clínico temprano en el curso de la enfermedad son lo inespecífico de sus síntomas y la sutileza de los hallazgos clínicos que pueden ser detectados por el médico en los estadíos iniciales de la enfermedad. El tiempo de evolución de los síntomas al momento de establecer el diagnóstico es aproximadamente 2 años y en aproximadamente el 10 % de los pacientes el diagnostico no se establece hasta después de tres años de iniciados los síntomas.

      Article visits 15 | PDF visits 87

      Downloads

      Download data is not yet available.
      1. Rich S, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med, 1987; 107(2): 216-23.
      2. Rubin L.J. and D.B. Badesch, Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med, 2005; 143(4): 282-92.
      3. Galie N, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Rev Esp Cardiol 2005; 58(5):523-66.
      4. Ahearn GS, et al. Electrocardiography to Define Clinical Status in Primary Pulmonary Hypertension and Pulmonary Arterial Hypertension Secondary to Collagen Vascular Disease. Chest 2002; 122(2):524-527.
      5. Satoh T. et al. Descriptive patterns of severe chronic pulmonary hypertension by chest radiography. Respiratory Medicine 2005; 99(3): 329-336.
      6. McGoon M, et al. Screening, Early Detection, and Diagnosis of Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines. Chest 2004; 126(1_suppl):14S-34.
      7. Galie N. et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004; 25(24):2243-78.
      8. Rubin LJ, Executive Summary: Diagnosis and Management of Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines. Chest 2004; 126(1_suppl): 4S-6.
      9. Borgeson DD, et al. Frequency of Doppler measurable pulmonary artery pressures. J Am Soc Echocardiogr 1996;9(6): 832-7.
      10. Denton CP. et al, Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Rheumatology 1997;36(2):239-243.
      11. Pilatis ND, et al. Clinical predictors of pulmonary hypertension in patients undergoing liver transplant evaluation. Liver Transpl 2000; 6(1): 85-91.
      12. Simonneau G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43(12 Suppl S): 5S-12S.
      13. Manes A, Campana C. Pulmonary hypertension: classification and diagnostic algorithm. Ital Heart J 2005; 6(10): 834-9.
      14. Pauwels RA, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Am. J. Respir. Crit. Care Med 2001; 163(5): 1256-1276.
      15. Fedullo PF, et al. Chronic Thromboembolic Pulmonary Hypertension. N Engl J Med 2001; 345(20): 1465-1472.
      16. Dartevelle P, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2004; 23(4): 637-648.
      17. Resten A, et al. Pulmonary Hypertension: CT of the Chest in Pulmonary Venoocclusive Disease. Am. J. Roentgenol 2004; 183(1): 65-70.
      18. Ley S, et al. Value of high spatial and high temporal resolution magnetic resonance angiography for differentiation between idiopathic and thromboembolic pulmonary hypertension: initial results. Eur Radiol 2005; 15(11): 2256-63.
      19. Castro O, Gladwin MT. Pulmonary hypertension in sickle cell disease: mechanisms, diagnosis, and management. Hematol Oncol Clin North Am 2005; 19(5): 881-96, vii.
      20. Bull TM, Fagan KA,Badesch DB., Pulmonary vascular manifestations of mixed connective tissue disease. Rheum Dis Clin North Am, 2005; 31(3): 451-64, vi.
      21. Strange C, Highland KB. Pulmonary hypertension in interstitial lung disease. Curr Opin Pulm Med 2005; 11(5): 452-5.
      22. Lee SH, Rubin LJ. Current treatment strategies for pulmonary arterial hypertension. J Intern Med 2005; 258(3): 199-215.
      23. Wilkins MR, et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study. Am. J. Respir. Crit. Care Med 2005; 171(11): 1292-1297.
      24. Sitbon O, et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 2005; 60(12): 1025-1030.
      25. Paramothayan NS, et al. Prostacyclin for pulmonary hypertension in adults. Cochrane Database Syst Rev 2005(2): p. CD002994.
      26. Liu C, Cheng J. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev 2005(1): CD004434.
      27. Lee AJ, Chiao TB, Tsang MP. Sildenafil for Pulmonary Hypertension. Ann Pharmacother 2005; 39(5): 869-884.
      28. Galie N, et al. Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. N Engl J Med 2005; 353(20): 2148-2157.
      29. Galie N, et al. Ambrisentan Therapy for Pulmonary Arterial Hypertension. Journal of the American College of Cardiology 2005; 46(3): 529-535.
      30. Humbert M, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004. 24(3): 353-359.
      31. Simonneau G. et al. Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension. A Double-blind, Randomized, Placebo-controlled Trial. Am. J. Respir. Crit. Care Med 2002; 165(6): 800-804.
      32. Rubin LJ, et al. Bosentan Therapy for Pulmonary Arterial Hypertension. N Engl J Med 2002; 346(12): 896-903.
      33. Wensel R, et al. Assessment of Survival in Patients With Primary Pulmonary Hypertension: Importance of Cardiopulmonary Exercise Testing. Circulation 2002; 106(3): 319-324.
      34. Barst RJ, et al. Sitaxsentan Therapy for Pulmonary Arterial Hypertension. Am. J. Respir. Crit. Care Med 2004; 169(4): 441-447.
      35. Barst RJ, et al. Beraprost therapy for pulmonary arterial hypertension. Journal of the American College of Cardiology 2003; 41(12): 2119-2125.
      36. Miyamoto S, et al. Clinical Correlates and Prognostic Significance of Six-minute Walk Test in Patients with Primary Pulmonary Hypertension. Comparison with Cardiopulmonary Exercise Testing. Am. J. Respir. Crit. Care Med 2000; 161(2): 487-492.
      37. Paciocco G, et al. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J 2001; 17(4): 647-652.
      38. Barst RJ, et al. Treatment of Pulmonary Arterial Hypertension With the Selective Endothelin-A Receptor Antagonist Sitaxsentan. Journal of the American College of Cardiology 2006; 47(10): 2049-2056.
      39. Hoeper MM, et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004; 24(6): 1007-1010.
      40. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327(2): 76-81.
      41. Badesch DB, et al. Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines. Chest 2004; 126(1_suppl): 35S-62.

      Information

      Journal history

      Keywords

      QR code

      Funding

      Support + Info: Here

       

       

      Directories and indexes

      Google Scholar profile

      Most read in the last 30 days

      Current Issue

      Sistema OJS 3.4.0.7 - Metabiblioteca |